- Home
- NAC vs AUPH Comparison
NAC vs AUPH Comparison
Compare NAC & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAC
- AUPH
- Stock Information
- Founded
- NAC 1998
- AUPH 1993
- Country
- NAC France
- AUPH Canada
- Employees
- NAC N/A
- AUPH N/A
- Industry
- NAC Investment Managers
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- NAC Finance
- AUPH Health Care
- Exchange
- NAC Nasdaq
- AUPH Nasdaq
- Market Cap
- NAC 1.6B
- AUPH 1.6B
- IPO Year
- NAC N/A
- AUPH 1999
- Fundamental
- Price
- NAC $11.98
- AUPH $13.17
- Analyst Decision
- NAC
- AUPH Strong Buy
- Analyst Count
- NAC 0
- AUPH 2
- Target Price
- NAC N/A
- AUPH $13.00
- AVG Volume (30 Days)
- NAC 307.3K
- AUPH 1.2M
- Earning Date
- NAC 01-01-0001
- AUPH 11-07-2025
- Dividend Yield
- NAC 4.33%
- AUPH N/A
- EPS Growth
- NAC N/A
- AUPH N/A
- EPS
- NAC N/A
- AUPH 0.42
- Revenue
- NAC N/A
- AUPH $260,111,000.00
- Revenue This Year
- NAC N/A
- AUPH $17.33
- Revenue Next Year
- NAC N/A
- AUPH $14.31
- P/E Ratio
- NAC N/A
- AUPH $31.33
- Revenue Growth
- NAC N/A
- AUPH 25.59
- 52 Week Low
- NAC $9.32
- AUPH $6.55
- 52 Week High
- NAC $11.21
- AUPH $13.54
- Technical
- Relative Strength Index (RSI)
- NAC 78.50
- AUPH 65.73
- Support Level
- NAC $11.81
- AUPH $11.96
- Resistance Level
- NAC $11.89
- AUPH $12.70
- Average True Range (ATR)
- NAC 0.09
- AUPH 0.44
- MACD
- NAC 0.01
- AUPH 0.15
- Stochastic Oscillator
- NAC 100.00
- AUPH 94.35
About NAC Nuveen California Quality Municipal Income Fund
Nuveen California Quality Municipal Income Fund is a diversified closed-end management investment company. Its objective is to provide current income exempt from regular federal and California income tax and to enhance portfolio value relative to the municipal bond market by investing in municipal securities that are exempt from federal and California state income taxes. It invests majority of its assets in securities that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.